The Quantellect read.As of Nov 19, 2026, 3 active firms cover Entrada Therapeutics Inc: 2 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $17.00 to $17.00, so the covering firms are broadly aligned. The average target of $17.00 sits 238% above the current $5.04. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.76 next quarter toward $-3.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy267%
Neutral133%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$17.00
+237.6% upside
Average target across 1 active firms as of Nov 19, 2026 vs $5.04 current
Highest Target$17.00
Average Target$17.00
Lowest Target$17.00
Detailed analyst forecasts for TRDA
Showing 1–2 of 2 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 2 of 3 active firms rate TRDA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TRDA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.76
Range $-1.10 – $-0.12 · 4 analysts · -21% YoY
Next period, 4 analysts expect Entrada Therapeutics Inc to earn $-0.76 a share (range $-1.10 – $-0.12), versus $-0.95 a year earlier. Full-year consensus is $-3.96, growing to $-3.40 the year after.
REVENUE · NEXT QUARTER
$18.3M
Range $0 – $45.0M · 4 analysts · +1995% YoY
Revenue is expected to reach $18.3M (range $0 – $45.0M), +1995.2% year-over-year. Full-year consensus is $4.0M, rising to $20.4M next year.
Top analysts covering Entrada Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TRDA.
#1
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$17.00+237.6% to target
Overall win rate
39%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Neutral
No targeton TRDA
Overall win rate
36%
+ Follow
#3
MM
Myles Minter
William Blair
Buy
No targeton TRDA
Coverage
—
+ Follow
#4
KB
Kostas Biliouris
Oppenheimer
Buy
$23.00+356.8% to target
Coverage
—
+ Follow
#5
Boobalan Pachaiyappan
Roth Capital
Buy
$10.00+98.6% to target
Coverage
—
+ Follow
TRDA stock forecast FAQ
What is TRDA's average 12-month price target?+
The 1 active firms with a live target average $17.00 for Entrada Therapeutics Inc over the next 12 months, ranging from a $17.00 high to a $17.00 low, as of Nov 19, 2026.
Is TRDA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover TRDA?+
3 active firms have a recognized rating on Entrada Therapeutics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TRDA?+
Among analysts who currently cover TRDA, Debjit Chattopadhyay of Guggenheim has the strongest overall Quantellect track record (Rank #248). Their current call is Buy with a $17.00 target.
What is Entrada Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.76 per share (range $-1.10 – $-0.12) across 4 analysts. Full-year EPS is projected at $-3.96, rising to $-3.40 the following year.
How much revenue is Entrada Therapeutics Inc expected to report next quarter?+
Consensus revenue is $18.3M (range $0 – $45.0M). Full-year revenue is projected at $4.0M, growing to $20.4M next year.
Have analysts been upgrading or downgrading TRDA lately?+
As of Nov 19, 2026, 2 of 3 active firms rate TRDA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TRDA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.